Investor Relations

Anesiva, Inc. (Nasdaq: ANSV) is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.

The investor pages that follow are your resource for financial information about Anesiva. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.

Featured Event

	Conference Call to Discuss Adlea ACTIVE-1 Results and Zingo Commercial Operations
	Nov 11, 2008 at 9:00 AM ET

Recent Releases

Jan 9, 2009
Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication

Dec 19, 2008
Anesiva Announces Changes to Its Board of Directors and Receives Notification From Nasdaq

FORWARD LOOKING STATEMENTS

This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Anesiva's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks related to the progress, timing and results of Anesiva's clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, and other risks detailed in Anesiva's filings with the Securities and Exchange Commission.